A Decreased Level of Serum Soluble Klotho Is an Independent Biomarker Associated with Arterial Stiffness in Patients with Chronic Kidney Disease

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Kitagawa, Masashi ^a   Sugiyama, Hitoshi ^a   Morinaga, Hiroshi ^a   Inoue, Tatsuyuki ^a,b   Takiue, Keiichi ^a   Ogawa, Ayu ^a   Yamanari, Toshio ^a   Kikumoto, Yoko ^a   Uchida, Haruhito Adam ^a   Kitamura, Shinji ^a   Maeshima, Yohei ^a   Nakamura, Kazufumi ^a   Ito, Hiroshi ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KLOTHO PROTEIN; PARATHYROID HORMONE; PHOSPHATASE; VITAMIN D;

ADULT; AGED; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; VITAMIN BLOOD LEVEL;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; FEMALE; GLUCURONIDASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULSE WAVE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION; VASCULAR STIFFNESS;

EID: 84874207539     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056695     Document Type: Article

References (72)

1. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY, (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305.
3. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, et al. (2006) Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953.
4. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl: pp. S1-130.
5. Moe SM, Drueke T, (2008) Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol 3 Suppl 3: S127-130.
6. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, et al. (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79: 1370-1378.
7. Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, et al. (2010) FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 78: 679-685.
8. Kuroo M, (2011) Phosphate and Klotho. Kidney Int Suppl 79: S20-S23.
9. John GB, Cheng CY, Kuroo M, (2011) Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis 58: 127-134.
10. Kuroo M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51.
11. Kuroo M, (2009) Klotho and aging. Biochim Biophys Acta (BBA)- General Subjects 1790: 1049-1058.
12. Saito Y, Nakamura T, Ohyama Y, Suzuki T, Iida A, et al. (2000) In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun 276: 767-772.
13. Kuwahara N, Sasaki S, Kobara M, Nakata T, Tatsumi T, et al. (2008) HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis. Int J Cardiol 123: 84-90.
14. Akimoto T, Shiizaki K, Sugase T, Watanabe Y, Yoshizawa H, et al. (2012) The relationship between the soluble Klotho protein and the residual renal function among peritoneal dialysis patients. Clin Exp Nephrol 16: 442-447.
15. Asai O, Nakatani K, Tanaka T, Sakan H, Imura A, et al. (2012) Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int 81: 539-547.
16. Hu MC, Shi M, Zhang J, Quinones H, Griffith C, et al. (2011) Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 22: 124-136.
17. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, et al. (2012) Serum levels of soluble secreted alpha-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 16: 722-729.
18. Hu M-C, Shi M, Zhang J, Quiñones H, Kuroo M, et al. (2010) Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int 78: 1240-1251.
19. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774.
20. Nagai R, Saito Y, Ohyama Y, Aizawa H, Suga T, et al. (2000) Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci 57: 738-746.
21. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, et al. (1998) Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248: 324-329.
22. Kusaba T, Okigaki M, Matui A, Murakami M, Ishikawa K, et al. (2010) Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci U S A 107: 19308-19313.
23. Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, et al. (2007) alpha-Klotho as a regulator of calcium homeostasis. Science 316: 1615-1618.
24. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, et al. (2005) Suppression of aging in mice by the hormone Klotho. Science 309: 1829-1833.
25. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, et al. (2004) Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett 565: 143-147.
26. Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR, (2007) Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A 104: 19796-19801.
27. Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, et al. (2010) Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun 398: 513-518.
28. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, et al. (2012) Relationship of low plasma klotho with poor grip strength in older community-dwelling adults: the InCHIANTI study. Eur J Appl Physiol 112: 1215-1220.
29. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, et al. (2011) Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc 59: 1596-1601.
30. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, et al. (2011) Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci 66: 794-800.
31. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, et al. (2012) Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125: 2243-2255.
32. Devaraj S, Syed B, Chien A, Jialal I, (2012) Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol 137: 479-485.
33. Komaba H, Koizumi M, Tanaka H, Takahashi H, Sawada K, et al. (2012) Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 27: 1967-1969.
34. Yokoyama K, Imura A, Ohkido I, Maruyama Y, Yamazaki Y, et al. (2012) Serum soluble alpha-klotho in hemodialysis patients. Clin Nephrol 77: 347-351.
35. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, et al. (2001) Severely Reduced Production of Klotho in Human Chronic Renal Failure Kidney. Biochem Biophys Res Commun 280: 1015-1020.
36. Sun C-Y, Chang S-C, Wu M-S, (2012) Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 81: 640-650.
37. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, et al. (2009) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 1551-1558.
38. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, et al. (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123.
39. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, et al. (2010) Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 24: 3438-3450.
40. Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, et al. (2005) Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28: 2890-2895.
41. Morimoto S, Yurugi T, Aota Y, Sakuma T, Jo F, et al. (2009) Prognostic significance of ankle-brachial index, brachial-ankle pulse wave velocity, flow-mediated dilation, and nitroglycerin-mediated dilation in end-stage renal disease. Am J Nephrol 30: 55-63.
42. Hanada S, Ando R, Naito S, Kobayashi N, Wakabayashi M, et al. (2010) Assessment and significance of abdominal aortic calcification in chronic kidney disease. Nephrol Dial Transplant 25: 1888-1895.
43. Ohya M, Otani H, Kimura K, Saika Y, Fujii R, et al. (2010) Improved Assessment of Aortic Calcification in Japanese Patients Undergoing Maintenance Hemodialysis. Intern Med 49: 2071-2075.
44. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, et al. (2011) Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 217: 486-491.
45. Chue CD, Edwards NC, Moody WE, Steeds RP, Townend JN, et al. (2012) Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. Heart 98: 219-224.
46. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, et al. (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18: 613-620.
47. Schillaci G, Pucci G, Pirro M, Monacelli M, Scarponi AM, et al. (2011) Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 218: 96-101.
48. Rosa J, Raska I Jr, Wichterle D, Petrak O, Strauch B, et al. (2011) Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens Res 34: 296-300.
49. Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, et al. (2012) FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 23: 2017-2025.
50. Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, et al. (2012) FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 27: 727-733.
51. Briet M, Bozec E, Laurent S, Fassot C, London GM, et al. (2006) Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 69: 350-357.
52. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, et al. (2010) Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 23: 282-289.
53. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, et al. (2001) Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987-992.
54. Kramann R, Couson SK, Neuss S, Kunter U, Bovi M, et al. (2011) Exposure to uremic serum induces a procalcific phenotype in human mesenchymal stem cells. Arterioscler Thromb Vasc Biol 31: e45-54.
55. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, et al. (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16: 520-528.
56. Di Marco GS, Konig M, Stock C, Wiesinger A, Hillebrand U, et al. (2012) High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int [Epub ahead of print].
57. Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, et al. (2012) Effects of phosphate on vascular function under normal conditions and influence of the uraemic state. Cardiovasc Res 96: 130-139.
58. Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, et al. (2012) Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7: 810-819.
59. Martin A, David V, Quarles LD, (2012) Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev 92: 131-155.
60. Wolf M, (2010) Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease. J Am Soc Nephrol 21: 1427-1435.
61. Seiler S, Wen M, Roth HJ, Fehrenz M, Flugge F, et al. (2012) Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int [Epub ahead of print].
62. Yoon HE, Ghee JY, Piao S, Song JH, Han DH, et al. (2011) Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy. Nephrol Dial Transplant 26: 800-813.
63. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro OM, et al. (2012) Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 82: 1261-1270.
64. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43: S1-290.
65. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, et al. (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11: 41-50.
66. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992.
67. Teragawa H, Kato M, Kurokawa J, Yamagata T, Matsuura H, et al. (2001) Usefulness of flow-mediated dilation of the brachial artery and/or the intima-media thickness of the carotid artery in predicting coronary narrowing in patients suspected of having coronary artery disease. Am J Cardiol 88: 1147-1151.
68. Uchida HA, Nakamura Y, Kaihara M, Norii H, Hanayama Y, et al. (2006) Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy. Nephrol Dial Transplant 21: 3475-3480.
69. Handa N, Matsumoto M, Maeda H, Hougaku H, Ogawa S, et al. (1990) Ultrasonic evaluation of early carotid atherosclerosis. Stroke 21: 1567-1572.
70. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, et al. (2003) Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 26: 615-622.
71. Kitagawa M, Sugiyama H, Morinaga H, Inoue T, Takiue K, et al. (2011) Serum High-Sensitivity Cardiac Troponin T Is a Significant Biomarker of Left-Ventricular Diastolic Dysfunction in Subjects with Non-Diabetic Chronic Kidney Disease. Nephron Extra 1: 166-177.
72. Morinaga H, Sugiyama H, Inoue T, Takiue K, Kikumoto Y, et al. (2012) Effluent Free Radicals are Associated with Residual Renal Function and Predict Technique Failure in Peritoneal Dialysis Patients. Perit Dial Int 32: 453-461.